For research use only. Not for therapeutic Use.
Olutasidenib（Cat No.:I019700）is a selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), developed for the treatment of acute myeloid leukemia (AML) and other IDH1-mutant cancers. By targeting the mutant IDH1 enzyme, olutasidenib reduces the production of the oncometabolite 2-hydroxyglutarate (2-HG), which promotes abnormal cell growth. This inhibition helps restore normal cellular differentiation and slows cancer progression. Olutasidenib has shown promise in patients with relapsed or refractory AML, offering a targeted therapeutic option with potential to improve remission rates and patient outcomes in IDH1-mutant cancers.
| Catalog Number | I019700 |
| CAS Number | 1887014-12-1 |
| Synonyms | 5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile |
| Molecular Formula | C18H15ClN4O2 |
| Purity | 99% |
| Target | IDH1 |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | IDH1- R132H:21.2 nM(IC50) |
| IUPAC Name | 5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile |
| InChI | InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1 |
| InChIKey | NEQYWYXGTJDAKR-JTQLQIEISA-N |
| SMILES | C[C@@H](C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N |
| Reference | [1]. JM Watts, et al. A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). [2]. Justin A. Caravella, et al. Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020. |
